Is car t therapy used in gastric cancer
Reading File
Searching PubMed
CAR-T cell therapy gastric cancer
Searching the Web
CAR-T cell therapy gastric cancer 2025 2026 clinical trials results
Reading Article
PMID: 39397869
Reading Article
PMID: 39923010
Finding Sources
Reading Article
PMID: 40448345
Reading File
Searching PubMed
CLDN18.2 CAR-T gastric cancer clinical trial
Searching the Web
CLAUDIN18.2 CAR-T gastric cancer clinical trial results 2025
Reading Article
PMID: 40460847
Reading Article
PMID: 38830992
I now have all the key data needed for a thorough answer. Here is the full picture:
CAR-T Cell Therapy in Gastric Cancer
Yes, CAR-T therapy is being actively investigated in gastric cancer and has now produced the first-ever positive randomized controlled trial of a CAR-T product in a solid tumor. Here is a breakdown:
What is CAR-T Therapy?
Chimeric antigen receptor (CAR) T-cell therapy involves engineering a patient's own T cells to express a receptor targeting a specific tumor antigen. The engineered cells are infused back to seek and destroy cancer cells expressing that antigen. In hematologic malignancies (e.g., leukemia, lymphoma) this approach is already FDA-approved and well-established. In solid tumors like gastric cancer, the challenge is greater due to antigen heterogeneity, a hostile immunosuppressive tumor microenvironment, and T-cell exhaustion.
Key Targets in Gastric Cancer
| Target | Rationale |
|---|---|
| CLAUDIN18.2 (CLDN18.2) | Most advanced target; expressed in ~40% of gastric cancers; absent from normal tissue except gastric mucosa |
| HER2 | Overexpressed in ~15-20% of gastric cancers |
| MUC1 | Mucin overexpressed in GI cancers |
| CEA (carcinoembryonic antigen) | Widely expressed in GI cancers |
| Mesothelin | Expressed in some gastric cancers |
CLDN18.2 is by far the most promising target and the focus of the most advanced clinical work.
Landmark Clinical Evidence
Phase I Trial - Satri-cel (CT041), Nature Medicine 2024 [PMID: 38830992]
- 98 patients with CLDN18.2-positive advanced gastrointestinal cancers (mostly gastric)
- ORR: 38.8%, disease control rate: 91.8%
- Median PFS: 4.4 months, median OS: 8.8 months
- Cytokine release syndrome (CRS) in 96.9% of patients, but all grade 1-2 (manageable)
- No dose-limiting toxicities, no treatment-related deaths, no neurotoxicity
Phase II RCT - CT041-ST-01, The Lancet 2025 [PMID: 40460847] - Historic
This was the first randomized controlled trial of CAR-T therapy in any solid tumor globally and was presented at the 2025 ASCO Annual Meeting.
- 156 patients with CLDN18.2-positive advanced gastric/GEJ cancer, refractory to ≥2 prior lines
- Randomized 2:1 to satri-cel (250×10⁶ cells, up to 3 infusions) vs. treatment of physician's choice (TPC)
- Primary endpoint (PFS): 3.25 months (satri-cel) vs. 1.77 months (TPC), HR 0.37, p<0.0001 - a highly significant improvement
- Grade ≥3 adverse events: 99% of satri-cel patients vs. 63% TPC (toxicity is real but manageable)
- 69% of satri-cel patients had peritoneal metastasis - a notoriously hard-to-treat scenario
As noted in Harrison's Principles of Internal Medicine (22nd ed., 2025): "Additional studies targeting Claudin 18.2 including those using chimeric antigen receptor (CAR) T cells are underway."
Current Regulatory Status
- Not FDA-approved for any indication in gastric cancer as of mid-2026
- The CT041-ST-01 phase II data (published May 2025) is the basis for potential future regulatory submissions
- No approval has been announced yet; the trial was conducted in China (Peking University Cancer Hospital)
Challenges Specific to Solid Tumors
- T-cell exhaustion - CAR-T cells lose function in the dense stromal environment of solid tumors
- Antigen heterogeneity - Not all tumor cells express the target, leading to immune escape
- Immunosuppressive microenvironment - Regulatory T cells, MDSCs, and tumor-derived factors dampen the response
- On-target/off-tumor toxicity - CLDN18.2 is expressed in normal gastric mucosa, causing gastric mucosal injury (seen in ~8% of patients in the phase I trial)
- Manufacturing complexity - Autologous CAR-T is expensive and time-consuming; patient fitness matters
Summary
| Aspect | Status |
|---|---|
| Main target | CLDN18.2 |
| Best agent | Satri-cel (CT041) |
| Highest evidence | Phase II RCT in The Lancet 2025 (first positive CAR-T RCT in solid tumors) |
| FDA approval | Not yet approved |
| Key finding | PFS HR 0.37 vs. physician's choice in 3rd+ line setting |
| Safety | CRS in most patients; generally grade 1-2; high rate of grade ≥3 AEs overall |
The CT041-ST-01 Lancet trial is the most significant milestone to date, and the phase I results in Nature Medicine provide the foundational safety and efficacy data that led to it. These results have generated significant excitement, as they represent the first randomized proof that CAR-T can work in a solid tumor - but regulatory approval and widespread clinical use are still pending.
This is a shared conversation. Sign in to Orris to start your own chat.